All News

Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.

Dexcom's Stelo will be available in summer 2024.

The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Test your pharmacy news knowledge with our weekly quiz: February 26 to March 1

Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.

Three times each year, the National Community Pharmacists Association holds intensive workshops that drill down into the nitty gritty of pharmacy ownership.

Pharmacy schools specialize in training students as experts in patient care—not as expert business owners.

These OTC products are recommended to address a variety of symptoms that occur during cold and flu seasons.

How much longer can independent pharmacists survive with the current method of reimbursement?

Your look at today’s health care headlines, including production challenges at a Aurobindo, Pfizer’s Super Bowl commercial, and Novo Nordisk’s semaglutide lawsuits.

The Affordable Care Act mandates that contraceptives must be covered by health plans and insurers without cost-sharing.

The lawsuit claims several pharmacy benefit managers, including Express Scripts and OptumRx, collaborated with manufacturers in “deceptive” and “dangerous” marketing.

Findings from the current study lend scientific credence to the idea that making informed dietary choices can help promote favorable health outcomes.

Just weeks after it gained FDA approval, pharmacy organizations have come forward to voice concerns about the safety and security of Florida’s drug importation program.

The CONVOKE study is investigating the effectiveness of the smartphone app as a therapy for negative symptoms of schizophrenia among adults.

A recent study found that reduced drug use was associated with a decrease in cravings, drug seeking behaviors, and depression severity.

According to Tyler Milliken, educating providers about prior authorization, along with other insurance processes and policies, plays a crucial role in advancing patients along their path to care.

In this conversation from the Healthcare Advocate Summit, Ned Woody, associate director of field reimbursement at Daiichi Sankyo Inc. - Oncology, discusses the disruptive impact that these programs have on patients.

Advocates can amplify the voices of transgender patients as they overcome barriers to health care, said Molly Crowther in a conversation at the 2023 Healthcare Advocate Summit.

By importing drugs in bulk from Canada, Florida aims to relieve the financial strain faced by patients who struggle to afford necessary medications.

The Starlyng-1 study showed that the treatment met its primary endpoint of a one-sided Cmin of >0.80; a one-sided Cmax of <1.25; and a two-sided Cavg of 0.80-1.40, with 90% confidence limits.

Check out our recap of last year's advancements made in the vaccine, biosimilar, and therapeutic spaces.

A Saturday Night Live skit has been met with criticism for its caricatured portrayal of patients with sickle cell disease, especially as the timing of its airing casts a dark shadow over the recent breakthrough FDA treatment approvals.

The nonprofit pharmaceutical company plans to begin fulfilling orders for RiVive more broadly in early 2023 and will make it available across the US for free of charge or at a low breakeven cost.